Oramed Pharmaceuticals Inc.

Company Snapshot: Oramed Pharmaceuticals Inc.

Last Change Volume High Low

Company Overview

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

Client News

  1. Feb 6 2019 Oramed to Present at BIO CEO & Investor Conference
  2. Jan 22 2019 Oramed Initiates Phase I Oral GLP-1 Study Under IND
  3. Jan 15 2019 Oramed Pharmaceuticals' CEO Letter to Shareholders
  4. Jan 9 2019 Oramed Receives Additional $3 Million Milestone Payment from HTIT